Pall ForteBio User Meeting: BLI and SPR for All Your Characterization Needs


Bethesda, MD


Date: Tuesday, April 25, 2017

Time: 8:30 - 3:45 ET

Location: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852

Network and knowledge-share with Octet, BLItz, and Pioneer system users. Hear from other scientists about their latest work on our label-free platforms, and learn about the newest additions to the Pall ForteBio family! Engage with our Applications Team to learn about how to improve your assays, workflow and join our tutorial session for an even more enriching learning experience.

Registration: The user meeting is free to attend, but reservations are required as seating is limited. Lunch is included.


Please Register


8:30 - 9:00

Arrival and Registration

9:00 - 9:05

Welcome Remarks

9:05 - 9:15

Pall ForteBio Technology Overview and Update

9:15 - 9:45

Octet, Your Friend in Vaccine Development: Assessing Antigenicity and Immunogenicity of HIV-1 Envelope Proteins by Bio-Layer Interferometry
Victor Ayala, Ph.D., Staff Scientist, ABL Inc.

Development of an antibody panel and comparative binding assay for evaluation of antigenicity across HIV envelope vaccine candidates. Use of Octet to characterize various isolates plus aid in envelope design, cell line selection and increase purification efficiency with an aim to produce better vaccine candidates in less time.

9:45 - 10:15

Determining Kinetics of Bacteriophages Using an Octet RED384 System
Patricia Buckley, Ph.D., Research Microbiologist, US Army ECBC

10:15 - 10:30

Break Session

10:30 - 11:00

Establishing a Platform Ligand-Binding Method on the Pall ForteBio Octet System
Carson Cameron, M.S., Sr. Research Associate, KBI Biopharma, Inc.

Platform based technology and methods are a popular process for the pharmaceutical industry. However, some analytical methods such as Potency, Kinetics, and Bioassays are difficult to standardize to a platform approach. Described here is the implementation of a Ligand-Binding Platform allowing for targeted method development of potency, kinetics/dose response, and titer methods, able to be completed in a single day. Development of a Dual-Target assay demonstrates troubleshooting a complex method using this straightforward platform approach.

11:00 - 11:30

Viral Quantitation Assay Development and Automation Using the Octet HTX System and Tecan EVO
Rachael Cohen, Associate Scientist, Merck & Co., Inc.

There is a need in vaccine development for quantitative mass assays to monitor process development. Traditional ELISA development resulted in an assay that lacked sensitivity, required multiple incubation steps and was prone to day to day variability. Using the Octet HTX, two mass quantitation assays for viral particles (>200 nm) were developed. This new technology allowed the use of two unique epitopes to quantitate viral mass and characterize the virus particle through cell culture and purification. Automating the assays on the Tecan EVO allowed walk away automation, and increased the throughput of the assay to six plates per run, with 5-9 samples, analyzed in duplicate, per plate in 2.5-3.5 hours.

11:30 - 12:00

Discovery and Characterization of Antibodies against Challenging Membrane Proteins and Viruses
Joseph Rucker, Ph.D., VP, Research and Development, Integral Molecular

Integral membrane proteins are important drug targets and monoclonal antibodies (MAbs) directed against them are highly sought for both research and therapeutic purposes. However, the complex structure of membrane proteins makes the discovery and characterization of these MAbs especially challenging. We have implemented a robust approach for the generation and characterization of antibodies against complex epitopes on many structural classes of membrane proteins including G protein-coupled receptors, transporters, and ion channels. Our approach combines DNA and virus-like particle (VLP) immunizations with B cell cloning and phage display to generate antibodies with specific biological properties. As a specific example, we have generated potent antibodies targeting the ligand-gated ion channel P2X3, a ligand-gated ion channel and a validated target for neuropathic pain. Thorough characterization of the P2X3 MAbs reveals that they bind diverse conformational epitopes on P2X3 with high specificity. Using VLPs coupled to an optical biosensor, we measured the sub-nanomolar affinity and kinetics of the binding of the MAbs to P2X3. The P2X3 MAbs inhibited ATP-mediated calcium influx in transfected cells and, more importantly, blocked 90% of neuronal currents in primary cells ex vivo, enabling further development of lead MAb candidates. The characterization of antibodies against other membrane proteins and viral Envelope proteins will also be discussed.

12:00 - 12:30

Overview of New Products from Pall ForteBio
Rashi Takkar, Product Manager, Pall ForteBio

Come and hear about the next big thing coming out of Pall ForteBio. Join us for more details!

12:30 - 1:30


1:30 - 2:00

Automated Optimization of IgG Production in CHO Cell Line Development
Michael Kowalski, Ph.D., Staff Applications Scientist, Beckman Coulter Life Sciences

Once an antibody-producing cell line has been identified, optimizing the culture media can yield higher titers. We automated a factorial design of experiment approach to identify the optimal culture conditions. The Biomek FXP Workstation prepared combinations of media components and plated cells in replicate conditions, generated sample and reagent plates for IgG titer analysis on the Octet HTX platform, and initiated imaging and XTT assays to discern the effect of media components on cell growth.

2:00 - 3:30

Tutorial: Meet the Experts

3:30 - 3:45

Closing Remarks